CoChat

Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation

Open access
Mead, Richard J., Shan, Ning, Reiser, H. Joseph, Marshall, Fiona, Shaw, Pamela J. · 2023 · Nature Reviews Drug Discovery

The DOI matches its Crossref record; 304 of the 310 references it cites were found in a registry or an index.

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating disease caused by degeneration of motor neurons. As with all major neurodegenerative disorders, development of disease-modifying therapies has proven challenging for multiple reasons. Nevertheless, ALS is one of the few neurodegenerative diseases for which disease-modifying therapies are approved. Significant discoveries and advances have been made in ALS preclinical models, genetics, pathology, biomarkers, imaging and clinical readouts over the last 10-15 years. At the same time, novel therapeutic paradigms are being applied in areas of high unmet medical need, including neurodegenerative disorders. These developments have evolved our knowledge base, allowing identification of targeted candidate therapies for ALS with diverse mechanisms of action. In this Review, we discuss how this advanced knowledge, aligned with new approaches, can enable effective translation of therapeutic agents from preclinical studies through to clinical benefit for patients with ALS. We anticipate that this approach in ALS will also positively impact the field of drug discovery for neurodegenerative disorders more broadly.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41573-022-00612-2

Cites

304 of 304 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 304 references

Cited by

See all 512

Metadata

Authors
Mead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J.
Affiliations
  • University of Sheffield (GB)
  • MSD (UK) Limited (United Kingdom) (GB)
Corresponding author
Shaw, Pamela J.
Venue
Nature Reviews Drug Discovery
Published
2022-12-21
Volume
22
Issue
3
Pages
185-212
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W4312045033
Cited by
505
References
310
Citations by year
2026: 108 · 2025: 178 · 2024: 156 · 2023: 62 · 2022: 1
FWCI
14.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
Funders
  • National Institute for Health and Care Research (NF-SI-0617-10077, IS-BRC-1215, IS-BRC-1215-20017)
  • Motor Neurone Disease Association (974-797)
  • Medical Research Council (MR/V027735/1)
  • NIHR Sheffield Biomedical Research Centre (IS-BRC-1215-20017, BRC-1215-20017)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Keywords
amyotrophic lateral sclerosis, motor neuron degeneration, disease-modifying therapy, translational research, neurodegenerative diseases, drug discovery, preclinical models, biomarkers, imaging, therapeutic target
MeSH terms
Amyotrophic Lateral Sclerosis, Humans, Motor Neurons, Biomarkers, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. https://app.cochat.ai/papers/10.1038/s41573-022-00612-2
The paper
Mead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023). Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-022-00612-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.